Navigation Links
Research: Improving treatment of patients with heart attack
Date:6/25/2009

This release is available in French.

Montreal, June 25th 2009 When faced with patients suffering a heart attack, doctors have two choices: inject them with medication to dissolve the blood clot (fibrinolytic therapy) or insert a small balloon to open the blocked artery (primary percutaneous coronary intervention (PCI)). Guidelines for treating heart attacks are generally based on clinical trials that do not take "real-life" conditions into account. The latest study by Dr. Thao Huynh of the Research Institute of the MUHC analyses these gaps and provides potential solutions to improve treatment of heart attack. Her article was published in the June 23rd issue of Circulation.

In this study, Dr. Huynh compares the results of 23 randomized controlled trials conducted under controlled experimental conditions, with the results of 32 observational studies reporting on the treatment of patients with heart attacks in routine clinical conditions.

Both types of studies show the superiority of PCI over fibrinolytic therapy in reducing mortality and the risk of further episodes of cardiac arrest and stroke over the short term. However, the advantage of PCI is even more apparent in randomized controlled trials where delays in providing primary PCI are shorter than in routine clinical conditions.

"This study indeed demonstrates that we have to work to reduce these delays if we are to maximize the effectiveness of PCI," explained Dr. Huynh. "When it comes to treating heart attack, reducing delays in providing treatment is the number one priority. It is also essential that patients with symptoms of heart attack seek prompt medical attention. Delays by patients to seek medical attention may further increase delays to treatment of heart attack. "

Analysis of randomized controlled trials shows that primary PCI also reduces long-term mortality and repeat heart attack. However, this long-term benefit of primary PCI is not observed in observational studies where patients receive treatment within routine clinical conditions.

"The benefit of primary PCI can be lost over the long term if patients are not receiving optimal medical therapy after discharge from hospital. These medications are essential to prevent repeat heart attack." warned Dr. Huynh.


'/>"/>

Contact: Isabelle Kling
isabelle.klign@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3
2. Radiological Society of North America research: Cancer risk from cardiac CT overstated
3. New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest
4. Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market
5. New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
6. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
7. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
8. Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care
9. Beth Israel Medical Center Receives Major American Cancer Society Grant Toward Improving Pain Management in Chinese Cancer Patients
10. United Spinal Associations 2009 Independence Expo Aug. 7th-8th In Orlando: Improving Life for the Disabled and the Aging
11. United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: